BioSpace News Archive

No changes to curcumin formulations, only name changing

Tmunity Therapeutics, Inc. is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy

CEO Craig Snyder will participate in a leadership panel presentation, “How Tech & Data are Shaping the Industry,” as part of the second annual State of the Cannabis Industry Conference to be held in Boston on October 4.

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.

Pandion is developing a new class of drugs to treat diseases with high unmet medical need, including inflammatory bowel disease, autoimmune liver disease, kidney diseases, type 1 diabetes, and autoimmune skin conditions.

Jnana Therapeutics was launched in 2017 to build the first drug discovery platform targeting the solute carrier family of metabolite transporters, which are the gates used by the cell to control metabolite movement.

Emmaus Life Sciences (Emmaus), a leader in sickle cell disease treatment, announced today that Kurt Kruger, Chief Financial Officer, will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018, at 9:45 a.m. ET in New York, New York.

Georgia Bio announced today keynote and featured speakers for its Annual Innovation Summit, Tues., Oct. 9, 2018 at Cobb Galleria.

Eyevance Pharmaceuticals, a Fort Worth-based pharmaceutical company committed to developing and commercializing innovative and impactful ophthalmic products, today announced a worldwide licensing agreement with OcuNexus Therapeutics for NEXAGON®, a 30-base antisense oligomer being developed for the orphan indication of persistent corneal epithelial defect (PED) nonresponsive to standard of care.

TeamHealth, a leading clinician services organization, announced today that Dan Collard will join the company as Executive Vice President (EVP) and Chief Growth Officer.